On October 13, XTALPI fell 5.08% in regular trading, trading at 6.58 HKD/share, with turnover of 59.84 million HKD.

Hong Kong-listed AI pharmaceutical names extended their post-holiday correction, with XTALPI dragged lower as a core AI drug discovery target. Earlier gains triggered concentrated profit-taking, while weaker risk appetite in overseas biotech pulled funds away from high-valuation innovative drug plays. Genscript Bio dropped 10.44%, Insilico fell 5.66%, Wuxi XDC lost 3.46%, Wuxi Bio declined 2.94%, and Wuxi Apptec slipped 1.73%.

XTALPI Holdings Limited provides drug and materials science R&D solutions and services for pharmaceutical and materials science industries, operating drug discovery solutions and intelligent robot solutions segments in domestic and overseas markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)